cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Caribou Biosciences
7 own
8 watching
Current Price
$7.6
$-0.18
(-2.31%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
463.5M
52-Week High
52-Week High
13.19
52-Week Low
52-Week Low
4.89
Average Volume
Average Volume
0.36M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization463.5M
icon52-Week High13.19
icon52-Week Low4.89
iconAverage Volume0.36M
iconDividend Yield--
iconP/E Ratio--
What does the Caribou Biosciences do?
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.
Read More
How much money does Caribou Biosciences make?
News & Events about Caribou Biosciences.
PR Newswire
1month ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Caribou Biosciences, Inc. - CRBU SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Caribou Biosciences, Inc. - CRBU PR Newswire NEW YORK, Jan. 4, 2023 NEW YORK, Jan. 4, 2023...
Globe Newswire
1month ago
NEW YORK, Jan. 01, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Caribou Biosciences, Inc. (Caribou or the Company) (NASDAQ:CRBU). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The ...
Business Wire
1month ago
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Caribou Biosciences, Inc. (Caribou or the Company) (NASDAQ: CRBU) for violations of the securities laws. The investigation focuses on whether the Company issued...
Business Wire
1month ago
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Caribou Biosciences, Inc. (Caribou or the Company) (NASDAQ: CRBU) for violations of the securities laws. The investigation focuses on whether the Company issued...
Frequently Asked Questions
Frequently Asked Questions
What is Caribou Biosciences share price today?
plus_minus_icon
Can Indians buy Caribou Biosciences shares?
plus_minus_icon
How can I buy Caribou Biosciences shares from India?
plus_minus_icon
Can Fractional shares of Caribou Biosciences be purchased?
plus_minus_icon
What are the documents required to start investing in Caribou Biosciences stocks?
plus_minus_icon
What is today’s traded volume of Caribou Biosciences?
plus_minus_icon
What is today’s market capitalisation of Caribou Biosciences?
plus_minus_icon
What is the 52-Week High and Low Range of Caribou Biosciences?
plus_minus_icon
What percentage is Caribou Biosciences down from its 52-Week High?
plus_minus_icon
What percentage is Caribou Biosciences up from its 52-Week Low?
plus_minus_icon
Current Price
$7.6
$-0.18
(-2.31%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00